Recent Updates — NVCR

NovoCure announced that Japan’s Ministry of Health, Labour and Welfare approved Optune Pax for treating unresectable locally advanced pancreatic cancer in adults, used concomitantly with gemcitabine and nab-paclitaxel. The approval was based on the Phase 3 PANOVA-3 trial, which demonstrated a statistically significant improvement in median overall survival compared to chemotherapy alone. NovoCure is a global oncology company developing and commercializing Tumor Treating Fields therapy for aggressive cancers.

Timothy Scannell retired from the Board of NovoCure Limited effective September 2, 2026. His departure followed five years of service and did not result from any disagreement with management. NovoCure Limited develops medical devices for cancer treatment.

Novocure reported second quarter 2026 net revenues of $183.6 million, a 16% year-over-year increase, driven by global active patient growth. The company also updated its full-year 2026 guidance, raising total net revenue to a range of $710 million - $725 million and Adjusted EBITDA to $0 million - $15 million. Novocure is a global oncology company that develops and commercializes Tumor Treating Fields (TTFields) therapy.

On June 30, 2026, NovoCure announced that its Optune Pax device received a CE Mark for treating adult patients with locally-advanced pancreatic cancer of exocrine origin, used alongside gemcitabine and nab-paclitaxel. The approval includes a reference to guideline recommendations to accommodate regional variations in the use of these chemotherapy agents. NovoCure is a medical device company that develops and commercializes Tumor Treating Fields (TTFields) for the treatment of cancer.

NovoCure Limited announced top-line results from its Phase 3 TRIDENT trial, which failed to demonstrate a statistically significant improvement in the primary endpoint of overall survival for the Early Start Arm compared to the Maintenance Start Arm. In the intent-to-treat population, the Early Start Arm had a median overall survival of 17.7 months versus 17.5 months (HR 0.953; p=0.519). TTFields therapy was well-tolerated with no new safety signals. NovoCure Limited is a medical technology company that develops and commercializes TTFields therapy for brain tumors.